Viridian Therapeutics, Inc. (VRDN)
NASDAQ: VRDN · Real-Time Price · USD
20.84
+1.53 (7.92%)
At close: Aug 4, 2026, 4:00 PM EDT
20.44
-0.40 (-1.92%)
After-hours: Aug 4, 2026, 7:34 PM EDT
Viridian Therapeutics Stock Forecast
Stock Price Forecast
According to 17 analysts polled by S&P Global, Viridian Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $36.13. The average 1-year stock price forecast is 73.37% higher than the current stock price, while the lowest is $22 (+5.57%) and the highest is $50 (+139.92%).
Price Target: $36.13 (+73.37%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Viridian Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 14 | 14 | 13 | 13 | 14 | 14 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 17 | 17 | 17 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $43 | Buy | Maintains | $43 | +106.33% | Aug 4, 2026 |
| Wells Fargo | Wells Fargo | Buy Reiterates $31 | Buy | Reiterates | $31 | +48.75% | Jul 20, 2026 |
| Stifel Nicolaus | Stifel Nicolaus | Buy Maintains $39 → $40 | Buy | Maintains | $39 → $40 | +91.94% | Jul 1, 2026 |
| Jefferies | Jefferies | Buy Maintains $30 | Buy | Maintains | $30 | +43.95% | Jun 30, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $34 → $35 | Buy | Maintains | $34 → $35 | +67.95% | Jun 30, 2026 |
Financial Forecast
Revenue This Year
27.65M
from 70.85M
Decreased by -60.97%
Revenue Next Year
231.54M
from 27.65M
Increased by 737.38%
EPS This Year
-3.80
from -3.32
EPS Next Year
-2.63
from -3.80
EPS and Forward PE are based on non-GAAP adjusted numbers.